Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: Patient selection and perspectives
© 2017 Catapano et al. Heterozygous familial hypercholesterolemia (FH) is a genetic disorder characterized by high low-density lipoprotein cholesterol levels from birth, which exposes the arteries to high levels of atherogenic lipoproteins lifelong and results in a significantly increased risk of p...
| Main Authors: | , , |
|---|---|
| Format: | Journal Article |
| Published: |
2017
|
| Online Access: | http://hdl.handle.net/20.500.11937/63283 |
| _version_ | 1848761044884783104 |
|---|---|
| author | Catapano, A. Pirillo, A. Norata, Giuseppe |
| author_facet | Catapano, A. Pirillo, A. Norata, Giuseppe |
| author_sort | Catapano, A. |
| building | Curtin Institutional Repository |
| collection | Online Access |
| description | © 2017 Catapano et al. Heterozygous familial hypercholesterolemia (FH) is a genetic disorder characterized by high low-density lipoprotein cholesterol levels from birth, which exposes the arteries to high levels of atherogenic lipoproteins lifelong and results in a significantly increased risk of premature cardiovascular events. The diagnosis of FH, followed by an appropriate and early treatment is critical to reduce the cardiovascular burden in this population. Phase I-III clinical trials showed the benefit of proprotein convertase subtilisin kexin 9 inhibitors, both alirocumab and evolocumab, in these patients with an average low-density lipoprotein cholesterol reduction ranging from −40% to −60%. The aim of this review is to address the unmet needs in cholesterol management, elucidate the biology and the clinical benefit of proprotein convertase subtilisin kexin 9 inhibition and finally discuss the open gaps and future directions in the treatment of patients with heterozygous FH. |
| first_indexed | 2025-11-14T10:25:25Z |
| format | Journal Article |
| id | curtin-20.500.11937-63283 |
| institution | Curtin University Malaysia |
| institution_category | Local University |
| last_indexed | 2025-11-14T10:25:25Z |
| publishDate | 2017 |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | curtin-20.500.11937-632832018-02-06T06:23:53Z Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: Patient selection and perspectives Catapano, A. Pirillo, A. Norata, Giuseppe © 2017 Catapano et al. Heterozygous familial hypercholesterolemia (FH) is a genetic disorder characterized by high low-density lipoprotein cholesterol levels from birth, which exposes the arteries to high levels of atherogenic lipoproteins lifelong and results in a significantly increased risk of premature cardiovascular events. The diagnosis of FH, followed by an appropriate and early treatment is critical to reduce the cardiovascular burden in this population. Phase I-III clinical trials showed the benefit of proprotein convertase subtilisin kexin 9 inhibitors, both alirocumab and evolocumab, in these patients with an average low-density lipoprotein cholesterol reduction ranging from −40% to −60%. The aim of this review is to address the unmet needs in cholesterol management, elucidate the biology and the clinical benefit of proprotein convertase subtilisin kexin 9 inhibition and finally discuss the open gaps and future directions in the treatment of patients with heterozygous FH. 2017 Journal Article http://hdl.handle.net/20.500.11937/63283 10.2147/VHRM.S130338 unknown |
| spellingShingle | Catapano, A. Pirillo, A. Norata, Giuseppe Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: Patient selection and perspectives |
| title | Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: Patient selection and perspectives |
| title_full | Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: Patient selection and perspectives |
| title_fullStr | Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: Patient selection and perspectives |
| title_full_unstemmed | Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: Patient selection and perspectives |
| title_short | Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: Patient selection and perspectives |
| title_sort | anti-pcsk9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives |
| url | http://hdl.handle.net/20.500.11937/63283 |